10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark one)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2013.

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number: 001-33930

IPC THE HOSPITALIST COMPANY, INC.

(Exact name of registrant as specified in its charter)

Delaware	95-4562058
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
4605 Lankershim Boulevard, Suite 617 North Hollywood, California	91602
(Address of principal executive offices)	(Zip code)

Registrant’s telephone number, including area code: (888) 447-2362

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	¨
Non-accelerated filer	¨  (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ¨    No  x

As of April 23, 2013, there were 16,765,161 shares of the registrant’s common stock, $0.001 par value, outstanding.

IPC The Hospitalist Company, Inc.

FORM 10-Q

QUARTERLY REPORT

TABLE OF CONTENTS

		Page
	PART I
Item 1	Consolidated Financial Statements (unaudited)
	Consolidated Balance Sheets - March 31, 2013 and December 31, 2012		3
	Consolidated Statements of Income - Three months ended March 31, 2013 and 2012		4
	Consolidated Statements of Cash Flows - Three months ended March 31, 2013 and 2012		5
	Notes to Consolidated Financial Statements		6
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations		14
Item 3	Quantitative and Qualitative Disclosures about Market Risk		20
Item 4	Controls and Procedures		20
	PART II
Item 1	Legal Proceedings		21
Item 6	Exhibits		21
Signatures			22
Exhibit Index			23

Note: Items 1A, 2, 3, 4 and 5 of Part II are omitted because they are not applicable.

2

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

IPC The Hospitalist Company, Inc.

Consolidated Balance Sheets

(dollars in thousands, except for share data)

	March 31, 2013		December 31, 2012
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	21,007	$	16,214
Accounts receivable, net		91,748		79,612
Insurance receivable for malpractice claims - current portion		10,437		9,719
Prepaid expenses and other current assets		13,036		17,284
Total current assets		136,228		122,829
Property and equipment, net		6,073		5,763
Goodwill		244,836		240,009
Other intangible assets, net		1,907		2,133
Deferred tax assets, net		250		250
Insurance receivable for malpractice claims - less current portion		18,338		17,074
Total assets	$	407,632	$	388,058
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities	$	8,096	$	4,257
Accrued compensation		33,411		28,615
Payable for practice acquisitions		23,206		29,038
Medical malpractice and self-insurance reserves, current portion		11,090		10,350
Deferred tax liabilities		1,506		1,506
Total current liabilities		77,309		73,766
Long-term debt		20,000		20,000
Medical malpractice and self-insurance reserves, less current portion		40,062		37,921
Total liabilities		137,371		131,687
Stockholders’ equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued		0		0
Common stock, $0.001 par value, 50,000,000 shares authorized, 16,753,021 and 16,694,215 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively		17		17
Additional paid-in capital		154,096		150,711
Retained earnings		116,148		105,643
Total stockholders’ equity		270,261		256,371
Total liabilities and stockholders’ equity	$	407,632	$	388,058

The accompanying notes are an integral part of these consolidated financial statements.

3

IPC The Hospitalist Company, Inc.

Consolidated Statements of Income

(dollars in thousands, except for per share data)

(unaudited)

	Three Months Ended March 31,
	2013			2012
Net revenue	$	153,091		$	129,793
Operating expenses:
Cost of services - physician practice salaries, benefits and other		112,068			95,098
General and administrative		23,823			20,074
Net change in fair value of contingent consideration		(1,093	)		84
Depreciation and amortization		1,154			848
Total operating expenses		135,952			116,104
Income from operations		17,139			13,689
Investment income		2			4
Interest expense		(115	)		(82	)
Income before income taxes		17,026			13,611
Income tax provision		6,521			5,105
Net income	$	10,505		$	8,506
Net income per share:
Basic	$	0.63		$	0.52
Diluted	$	0.61		$	0.50

The accompanying notes are an integral part of these consolidated financial statements.

4

IPC The Hospitalist Company, Inc.

Consolidated Statements of Cash Flows

(dollars in thousands)

(unaudited)

	Three Months Ended March 31,
	2013			2012
Operating activities
Net income	$	10,505		$	8,506
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		1,154			848
Stock-based compensation expense		1,735			1,464
Net change in fair value of contingent consideration		(1,093	)		84
Changes in assets and liabilities:
Accounts receivable		(12,136	)		(8,198	)
Prepaid expenses and other current assets		4,248			2,725
Accounts payable and accrued liabilities		3,839			3,006
Accrued compensation		4,796			5,584
Medical malpractice and self-insurance reserves, net		899			913
Net cash provided by operating activities		13,947			14,932
Investing activities
Acquisitions of physician practices		(9,691	)		(26,222	)
Purchase of property and equipment		(1,113	)		(1,105	)
Net cash used in investing activities		(10,804	)		(27,327	)
Financing activities
Proceeds from long-term debt		0			15,000
Net proceeds from issuance of common stock		1,333			1,777
Excess tax benefits from stock-based compensation		317			186
Net cash provided by financing activities		1,650			16,963
Net increase in cash and cash equivalents		4,793			4,568
Cash and cash equivalents, beginning of period		16,214			17,752
Cash and cash equivalents, end of period	$	21,007		$	22,320
Supplemental disclosure of cash flow information
Cash paid for:
Interest	$	75		$	31
Income taxes	$	490		$	627

The accompanying notes are an integral part of these consolidated financial statements.

5

IPC The Hospitalist Company, Inc.

Notes to the Consolidated Financial Statements

(Unaudited)

March 31, 2013

Note 1. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

IPC The Hospitalist Company, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time hospitalist practices. We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. The consolidated financial statements include all accounts of IPC The Hospitalist Company, Inc. and its wholly owned subsidiaries and consolidated professional medical corporations (Professional Medical Corporations) managed under long-term management agreements.

Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have controls over the operations of these VIE’s. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.

In our opinion, these consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to GAAP and SEC rules and regulations, which are applicable to interim financial statements. As a result, the following disclosures should be read in conjunction with our audited consolidated financial statements and notes thereto as of December 31, 2012 included in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC on February 26, 2013.

Revenue

Net revenue consists of fees for medical services provided by our affiliated hospitalists under fee-for-service, case rate and other professional fee arrangements with various payors including Medicare, Medicaid, managed care organizations, insurance companies and hospitals. Net revenue is reported in the period in which services are provided at amounts expected to be collected, which excludes contractual discounts and an estimate of uncollectible accounts.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. The process of estimating these assets and liabilities involves judgment decisions, which are subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2013.

Fair Value of Financial Instruments

Our consolidated balance sheets as of March 31, 2013 and December 31, 2012 included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit in December 2012 approximated its fair value at March 31, 2013 and December 31, 2012. Pursuant to GAAP, we determine the fair value of our long-term borrowing using quoted market prices, which is defined as Level 2 input under GAAP on fair value measures.

Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions, which is carried at fair value determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. The remaining amount of our payable for practice acquisitions is recorded at its carrying value, which approximates its fair value due to the relatively short period of time between its origination and its expected realization. See Note 3 for more information.

6

Goodwill

The changes in the carrying amount of goodwill for the three months ended March 31, 2013 are as follows (in thousands):

Goodwill - beginning balance at January 1, 2013	$	240,009
Goodwill acquired during 2013		6,886
Adjustment for prior year transactions		(2,059	)
Goodwill - ending balance at March 31, 2013	$	244,836

The valuation studies related to the practice acquisitions that occurred in the fourth quarter of 2012 have been completed, and as a result, the related valuations as of the acquisition dates have been reduced by $2,059,000, which is reflected in the above table.

Medical Malpractice Liability Insurance

We record our medical malpractice reserves, on an undiscounted basis, for claims incurred and reported and claims incurred but not reported (IBNR) during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP. Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):

	March 31, 2013								December 31, 2012
	Assets		Liabilities						Assets		Liabilities
	Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities		Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities
Current Portion	$	10,437	$	10,488		602		11,090	$	9,719	$	9,846		504		10,350
Long-term Portion		18,338		18,338		21,724		40,062		17,074		17,074		20,847		37,921
Total	$	28,775	$	28,826		22,326		51,152	$	26,793	$	26,920		21,351		48,271

Note 2. Practice Acquisitions

We recognize all of the assets acquired, liabilities assumed and any contingent consideration at the acquisition-date fair value and expense all transaction related costs.

During the three months ended March 31, 2013, in connection with the acquisition of assets of two hospitalist physician practices, we recorded goodwill and other identifiable intangible assets consisting of physician and hospital agreements. Amounts recorded as goodwill and identifiable intangible assets are not amortizable for GAAP financial reporting purpose but are amortized for tax purposes over 15 years. The results of operations of these acquisitions are included in the consolidated financial statements from the respective dates of acquisition.

In addition to the initial consideration paid at the close of each transaction, the asset purchase agreements for the two acquisitions completed during the three months ended March 31, 2013 provide for contingent consideration to be paid, which is generally based upon the achievement of certain operating results of the acquired practices as of certain measurement dates. These additional payments are not contingent upon the future employment of the sellers. The contingent consideration for these acquisitions was recorded on a provisional basis pending completion of the valuation studies as of the acquisition dates.

We estimate the fair value of contingent consideration to be paid based on discounted projected earnings of the acquired practices as of certain measurement dates. The discount rate that we use consists of a risk-free U.S. Treasury bond yield plus a Company specific credit spread which we believe is acceptable by willing market participants.

7

The following table summarizes the total amounts recorded during the three months ended March 31, 2013, related to the acquisition of hospitalist practices (in thousands):

Acquired assets - paid and accrued:
Goodwill - 2013 transactions	$	6,886
Other intangible assets		110
Fixed assets		15
Total acquired assets - 2013		7,011
Goodwill - adjustment for prior year transactions		(2,059	)
		4,952
Cash paid for acquisitions:
2013 transactions		(5,700	)
Contingent consideration		(3,918	)
Other - prior year transactions		(73	)
Total cash paid for acquisitions		(9,691	)
Decrease in payable for practice acquisitions		(4,739	)
Net change in fair value of contingent consideration		(1,093	)
Net change in payable for practice acquisitions		(5,832	)
Payable for practice acquisitions, beginning of period		29,038
Payable for practice acquisitions, end of period	$	23,206

Note 3. Fair Value Measurement

Some of our liabilities are measured and recorded at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The established fair value hierarchy distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (Levels 1 and 2) and the reporting entity’s own assumptions about market participant assumptions (Level 3). This hierarchy is used to measure fair value as follows:

• Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities.

• Level 2 inputs include quoted prices for similar assets and liabilities in active markets; quoted prices in markets that are not active; and other inputs that are observable or can be corroborated by observable market data for the asset or liability.

• Level 3 inputs are unobservable inputs for the asset or liability that are supported by little or no market activity.

The following table presents our liabilities measured at fair value on a recurring basis as of March 31, 2013 (in thousands):

	Quoted Price In Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Balance
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	$	0	$	0	$	22,975	$	22,975

8

The following table presents a rollforward of our liabilities measured at fair value on a recurring basis using significant unobservable inputs (level 3) for the three months ended March 31, 2013 (in thousands):

	Three Months Ended March 31, 2013
Accrued contingent consideration for practice acquisitions
Beginning balance	$	28,834
Addition through acquisition transactions		1,211
Adjustment for prior year transactions		(2,059	)
Change in fair value realized		(1,093	)
Payments		(3,918	)
Ending balance	$	22,975

Our payable for practice acquisitions totaling $23,206,000 at March 31, 2013 is composed of $22,975,000 of accrued contingent consideration measured at fair value, and $231,000 of other practice acquisition liabilities recorded at undiscounted carrying value which approximates fair value. The fair value of our accrued contingent consideration is determined using widely accepted valuation techniques, which include the income approach for estimating future consideration to be paid based on projected earnings of our acquired practices as of specified measurement dates. The income approach involves the use of a probability-weighted discounted cash flow model based on significant inputs not observable in the market. The significant inputs include a discount rate of 2.6%, and 100% probability of achieving the estimated projected earnings.

Because our accrued contingent consideration is generally based on a certain multiple of earnings of the acquired practices during a specified measurement period, a relatively small change in such projected earnings may result in a material change to the fair value of such contingent consideration liability with a corresponding adjustment to income from operations. We reassess our projected earnings and the related fair value of our accrued contingent consideration for practice acquisitions on a quarterly basis.

Note 4. Debt

Our secured revolving credit agreement (Credit Facility) provides a revolving line of credit of $75.0 million and contains an “accordion” feature that allows an increase of up to $25.0 million to the Credit Facility with lender approval. The Credit Facility has a maturity date of August 4, 2016 and is available for working capital, practice acquisitions, capital expenditures and general business expenses. As of March 31, 2013, we had long-term borrowings of $20.0 million and letters of credit of $0.2 million outstanding, and $54.8 million available under the Credit Facility.

The revolving line of credit is limited by a formula based on a certain multiple times the trailing twelve months of earnings before interest, taxes, depreciation, amortization and certain non-cash items. Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.25%, or the lender’s prime rate plus 0% to 0.25%, both based on a leverage ratio. We pay an unused commitment fee equal to 0.25% per annum on the difference between the revolving line capacity and the average balance outstanding during the year. Outstanding amounts advanced to us under the revolving line of credit are repayable on or before the maturity date. The interest rate for our borrowings under the Credit Facility at March 31, 2013 was 1% per annum.

The Credit Facility is guaranteed by our subsidiaries and affiliated Professional Medical Corporations and limited liability companies, and is secured by substantially all of our and our guarantors’ tangible and intangible assets. The Credit Facility includes various customary financial covenants and restrictions, as well as customary remedies for our lenders following an event of default. As of March 31, 2013, we were in compliance with such financial covenants and restrictions.

9

Note 5. Income Taxes

Following are the income tax provisions and effective tax rates for the three months ended March 31, 2013 and 2012 (dollars in thousands):

	Three Months Ended March 31,
	2013			2012
Income tax provision	$	6,521		$	5,105
Effective tax rate		38.3	%		37.5	%

The increase in the effective tax rate during 2013 as compared to the same period of 2012 was primarily related to a change in state tax laws in November 2012. The effective tax rates differ from the statutory U.S. federal income tax rate of 35.0% due primarily to state income taxes.

Our accounting policy is to include interest and penalties related to income tax liabilities in income tax expense. As of March 31, 2013, we did not have any estimated interest and penalties related to uncertain tax positions.

The tax years 2008 to 2011 remain open to examination by the major taxing jurisdictions to which we are subject. The statute of limitations for tax years 1999 to 2007 has expired, except that the tax year 1999 is subject to adjustment of net operating losses by the Internal Revenue Service. We are subject to taxation in the United States and various state jurisdictions. One federal examination has been initiated for our company and subsidiaries and one state examination has been initiated for one of our subsidiaries. The outcome of such examination cannot be predicted with certainty; however, we believe that the ultimate resolution will not have a material effect on our financial position, results of operations or cash flows.

We make our best estimate of the tax rate expected to be applicable for the full fiscal year. The rate so determined is used to compute our income tax expense for an interim period.

Note 6. Stock-Based Compensation

At March 31, 2013, we had a stock-based employee compensation program, for which we had reserved a total of 4,943,170 common shares for issuance. Under our 2012 Equity Participation Plan (Equity Plan), which was approved by our stockholders on June 7, 2012, a total of 1,422,130 shares of our common stock are available for issuance and no new awards will be issued under any previous equity participation plans. As of March 31, 2013, there were 1,132,018 shares of our common stock available for future grants under our Equity Plan, which included the canceled and forfeited shares issued under previous equity participation plans.

All option awards granted during the three months ended March 31, 2013 were issued with exercise prices equal to the closing price of our common stock on the NASDAQ Global Select Market on the dates of the grant. The options under the Equity Plan generally vest over a four-year period from date of grant, and unrestricted options terminate on the 10th anniversary of the agreement date for all grants issued before January 1, 2013 and on the 7th anniversary of the agreement date for all grants issued after December 31, 2012. Restricted stock awards generally vest over a four-year period from date of the award and performance stock awards generally vest over two to three years from date of the award.

Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):

	Three months ended March 31,
	2013		2012
Stock-based compensation expense	$	1,735	$	1,464

10

As of March 31, 2013, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and previous equity participation plans and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands).

	Total Unrecognized Compensation Cost		Weighted-average Remaining Contractual Term
			(Years)
Stock option	$	7,173		6.75
Restricted/Performance stock	$	7,241		2.03

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions:

	Three months ended March 31,
	2013			2012
Risk-free interest rate		0.66	%		1.21	%
Expected volatility		40.09	%		39.86	%
Expected option life (in years)		4.42			6.16
Expected dividend yield		0.00	%		0.00	%

The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero coupon issues. The expected volatility is based on historical volatility levels of our public company peer group and the volatility of our stock price since our initial public offering in January 2008. The expected option life of each award granted was calculated using the “simplified method” in accordance with GAAP.

The grant date fair value of each restricted stock award or performance stock award is based on the closing stock price on the grant date of the award as reported by NASDAQ Global Select Market.

The following table summarizes the stock option activities in our Equity Plan during the three months ended March 31, 2013.

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value		Weighted- Average Fair Value
						(Years)		(in 000s)
Options outstanding as of December 31, 2012		1,630,921		$	28.36					$	11.95
Changes during period:
Granted		44,468			41.55						13.97
Exercised		(30,252	)		12.03						4.67
Cancelled/Forfeited		0			—						—
Expired		(26	)		1.60						6.83
Options outstanding as of March 31, 2013		1,645,111		$	29.02		6.75	$	25,936	$	12.13
Options exercisable as of March 31, 2013		1,191,721		$	24.90		6.27	$	23,607	$	7.61

11

The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the three months ended March 31, 2013.

	Shares			Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value		Weighted- Average Fair Value
				(Years)		(in 000s)
Restricted/performance stock awards outstanding as of December 31, 2012		101,940						$	38.03
Changes during period:
Granted		124,642							42.04
Released		(10,432	)						39.33
Restricted/performance stock awards outstanding as of March 31, 2013		216,150			2.03	$	8,306	$	40.28

Note 7. Earnings Per Share

Basic net income per share is calculated by dividing net income for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing net income for the period by the weighted average number of shares outstanding during the period plus the dilutive effect of our outstanding stock awards and shares issuable under our employee stock purchase plan using the treasury stock method.

The calculations of basic and diluted net income per share for the three months ended March 31, 2013 and 2012 are as follows (dollars in thousands, except for per share data):

	Three Months Ended March 31,
	2013		2012
Basic:
Net income	$	10,505	$	8,506
Weighted average number of common shares outstanding		16,703,369		16,505,047
Basic net income per share	$	0.63	$	0.52
Diluted:
Net income	$	10,505	$	8,506
Weighted average number of common shares outstanding		16,703,369		16,505,047
Weighted average number of dilutive common shares equivalents from stock options		422,571		355,608
Common shares and common share equivalents		17,125,940		16,860,655
Diluted net income per share	$	0.61	$	0.50

As of March 31, 2013, 614,000 outstanding stock options are excluded from our diluted computation because their exercise option price is above market, or they are anti-dilutive under the treasury stock method.

12

Note 8. Commitments and Contingencies

Legal

In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated hospitalists. We may also become subject to other lawsuits, which could involve significant claims and/or significant defense costs.

We believe, based upon our review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, or cash flows in a future period.

Government Inquiry

On June 7, 2010, we received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. The CID requested information concerning claims that we have submitted to Medicare and Medicaid. The CID covered the period from January 1, 2003, through June 4, 2010, and requested production of a range of documents relating to our Medicare and Medicaid participation, physician arrangements, operations, billings and compliance programs. We believe we have a strong compliance focus, and that we operate with appropriate billing policies, procedures, provider training, and compliance programs and controls. We have produced responsive documents, will discuss with representatives of the government additional future productions to be made if requested and will continue to cooperate in the government investigation. We have been informed by the DOJ that a qui tam whistleblower complaint related to this investigation naming the Company has been filed under court seal in the U.S. District Court for the Northern District of Illinois (Chicago). We also have been informed that several state attorneys general are examining our Medicaid claims in coordination with the DOJ. It is not possible to predict whether or when this matter may be resolved or what impact, if any, the outcome of this matter might have on our consolidated financial position, results of operations, or cash flows.

13

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following management’s discussion and analysis should be read in conjunction with the unaudited consolidated financial statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our most recent Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission (SEC) on February 26, 2013.

The following discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding future events and the future results of IPC that are based on management’s current expectations, estimates, projections, and assumptions about our business. Words such as “may,” “will,” “could,” “should,” “target,” “potential,” “project,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “sees,” “estimates” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including, but not limited to, those discussed in our most recent Annual Report on Form 10-K, including the section entitled “Risk Factors,” as well as those discussed from time to time in the Company’s other SEC filings and reports. In addition, such statements could be affected by general industry and market conditions. Such forward-looking statements speak only as of the date of this Quarterly Report or, in the case of any document incorporated by reference, the date of that document, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this Report, or for changes made to this document by wire services or internet service providers. If we update or correct one or more forward-looking statements, investors and others should not conclude that we will make additional updates or corrections with respect to other forward-looking statements.

Company Overview and Recent Developments

We are a leading provider of hospitalist services in the United States. Hospitalist medicine is organized around inpatient care and is focused on providing, managing and coordinating the care of hospitalized patients. Hospitalists practice in inpatient facilities, including acute care hospitals, long-term care facilities, specialty hospitals, psychiatric facilities and post-acute care facilities. We believe we are the largest dedicated hospitalist company in the United States based on revenues, patient encounters and number of affiliated hospitalists. Our early entry into the emerging hospitalist industry has permitted us to establish a reputation and leadership position that we believe is closely identified with hospitalist medicine.

Practice Acquisitions

During the three months ended March 31, 2013, we acquired the assets of two hospitalist physician practices for a total estimated purchase price of $7,011,000. In connection with these acquisitions, we recorded property and equipment of $15,000, goodwill of $6,886,000 and identifiable intangible assets of $110,000. Total transaction costs of $3,000 for our acquisition activities during the three months ended March 31, 2013 were expensed as incurred.

In connection with these acquisitions, we recorded liabilities of $1,211,000 representing the fair value of future contingent considerations to be paid based upon the estimated achievement of certain operating results of the acquired practices as of certain measurement dates. The fair value of such contingent considerations is re-evaluated on a quarterly basis based on changes in our estimate of the operating results of future payments. The changes, if any, in fair value are recognized in our results of operations.

Rate Changes by Government Sponsored Programs

The Medicare program reimburses for our services based upon the rates set forth in the annually updated Medicare Physician Fee Schedule, which relies, in part, on a target-setting formula system called the Sustainable Growth Rate (SGR). Many private payors use the Medicare Physician Fee Schedule to determine their own reimbursement rates. Effective January 1, 2013, the Medicare update resulted in a slight increase in our net patient revenue per encounter.

The annual Medicare Physician Fee Schedule update, based on the SGR, is adjusted to reflect the comparison of actual expenditures to target expenditures. Because one of the factors for calculating the SGR is linked to the growth in the U.S gross domestic product (GDP), the SGR formula may result in a negative payment update if growth in Medicare beneficiaries’ use of services exceeds GDP growth, a situation which has occurred every year since 2002 and the reoccurrence of which we cannot predict.

The SGR payment update for 2013 would have been a cut of 26.5 percent; however, the American Taxpayer Relief Act of 2012, enacted on January 2, 2013, delayed the implementation of the negative SGR payment update until January 1, 2014. While Congress has repeatedly intervened to mitigate the negative reimbursement impact associated with the SGR formula, there is no guarantee that Congress will continue to do so in the future. Moreover, the existing methodology may result in significant yearly fluctuations in the Medicare Physician Fee Schedule amounts, which may be unrelated to changes in the actual costs of providing physician services. Unless Congress enacts a change in the SGR methodology, the uncertainty regarding reimbursement rates and fluctuation will continue to exist.

14

Another provision that affects physician payments is an adjustment under the Medicare statute to reflect the geographic variation in the cost of delivering physician services, by comparing those costs to the national average. This concerns the “work” component of the Geographic Practice Cost Indices (GPCI). If Congress does not block this adjustment, payments would be decreased to any geographic area with an index of less than 1.0. The enactment of the American Taxpayer Relief Act of 2012 again delayed the GPCI payment adjustment through the end of 2013. Although Congress has delayed the GPCI payment adjustment several times, there is no guarantee that Congress will block the adjustment in the future, which could result in a decrease in the payments we receive for physician services.

The Budget Control Act of 2011 (BCA) established a Joint Select Committee on Deficit Reduction, which was tasked with achieving a reduction in the federal debt level of at least $1.2 trillion. That Committee did not draft a proposal by the BCA’s deadline. As a result, automatic cuts in various federal programs were scheduled to take place, beginning in January 2013, including a two percent cut in Medicare payments to providers. The American Taxpayer Relief Act of 2012 again delayed implementation of the BCA’s automatic cuts until March 1, 2013, and on March 1, 2013, President Obama signed a sequestration order that triggered the BCA’s automatic cuts, including the two percent cut in Medicare payments to providers that was implemented effective April 1, 2013. This two percent net reduction in Medicare reimbursement rates for the codes applicable to the services performed by our affiliated hospitalists could reduce our net patient revenue per encounter by approximately 1.0 percent.

In addition to sequestration, the current instability of the federal budget may lead to legislation that could result in further cuts in Medicare and Medicaid payments to providers.

Healthcare Reform

In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, ACA) was enacted. The ACA includes a number of provisions that may affect our Company, although the impact of many of the changes will be unknown until they are implemented, which in some cases will not occur for a couple of years. The impact of some of these provisions have already proven to be positive, such as the ten percent Medicare bonus payment for primary care services (including outpatient and nursing home visits) from 2011 through 2015 to primary care practitioners for whom primary care services represented a minimum of 60 percent of Medicare allowed charges in a prior period, and the increase in Medicaid rates up to the level of Medicare rates (Medicaid Parity) in 2013 and 2014 for primary care services. Another positive provision is the expansion in the number of individuals with health insurance starting in January 2014.

The impact of other provisions is unknown at this time, such as the establishment of an Independent Payment Advisory Board that could recommend changes in payment for physicians under certain circumstances not earlier than January 15, 2014, which the U.S. Department of Health and Human Services (HHS) generally would be required to implement unless Congress enacts superseding legislation. Fraud and abuse penalty increases and the expansion in the scope of the reach of the federal False Claims Act and other government enforcement tools may adversely impact entities in the healthcare industry, including our Company.

The impact of certain provisions will depend upon the ultimate method of implementation. For example, the ACA requires HHS to develop a budget neutral value-based payment modifier that provides for differential payment under the Medicare Physician Fee Schedule for physicians or groups of physicians that is linked to quality of care furnished compared to cost. HHS has begun implementing the modifier through the Medicare Physician Fee Schedule rulemaking for 2013, by, among other things, specifying the initial performance period and how it will apply the upward and downward modifier for certain physicians and physician groups beginning January 1, 2015, as well as all physicians and physician groups starting not later than January 1, 2017. During this rulemaking process, HHS considered whether it should develop a value-based payment modifier option for hospital-based physicians, but ultimately, HHS decided to deal with this issue in future rulemaking. The impact of this payment modifier cannot be determined at this time.

In addition, certain provisions of the ACA authorize voluntary demonstration projects, which include the development of bundling payments for acute, inpatient hospital services, physician services, and post-acute services for episodes of hospital care. The Medicare Acute Care Episode Demonstration is currently underway at five health care system demonstration sites. The impact of these projects on our Company cannot be determined at this time.

15

Seasonality and Quarterly Fluctuations

We have historically experienced and expect to continue to experience quarterly fluctuations in net revenue and income from operations. Absent the impact and timing of acquisitions, our net revenue has historically been higher in the first and fourth quarters of the year primarily due to the following factors:

• the number of physicians we have on staff during the quarter, which may fluctuate based upon the timing of hires due to the end of the academic year for graduating resident physicians, the schedule of the Internal Medicine Board exams and terminations in our existing practices; and

• fluctuations in patient encounters, which are impacted by hospital census, which can be volatile, and physician productivity and often reflect seasonality due to the higher occurrence of illnesses such as flu and pneumonia in patient populations in the first quarter.

We have significant fixed operating costs, including physician practice salaries and benefits and, as a result, are highly dependent on patient encounters and the productivity of our affiliated hospitalists to sustain profitability. Additionally, quarterly results may be affected by the timing of practice acquisitions and the hiring and termination of our affiliated hospitalists.

16

Results of Operations and Operating Data

The following table sets forth operating data and selected consolidated statements of income information stated as a percentage of net revenue:

	Three Months Ended March 31,
	2013			2012
Operating data - patient encounters		1,576,000			1,355,000
Net revenue		100.0	%		100.0	%
Operating expenses:
Cost of services - physician practice salaries, benefits and other		73.2	%		73.3	%
General and administrative		15.6	%		15.5	%
Net change in fair value of contingent consideration		(0.7	)%		0.1	%
Depreciation and amortization		0.7	%		0.6	%
Total operating expenses		88.8	%		89.5	%
Income from operations		11.2	%		10.5	%
Investment income		—	%		—	%
Interest expense		(0.1	)%		—	%
Income before income taxes		11.1	%		10.5	%
Income tax provision		4.2	%		3.9	%
Net income		6.9	%		6.6	%

Three months ended March 31, 2013 compared to three months ended March 31, 2012

Our patient encounters for the three months ended March 31, 2013 increased by 221,000 encounters or 16.3% to 1,576,000, compared to 1,355,000 for the same period in the prior year. Net revenue for the three months ended March 31, 2013 was $153.1 million, an increase of $23.3 million, or 18.0%, from $129.8 million for the three months ended March 31, 2012. Of this $23.3 million increase, 77% was attributable to same-market area growth and 23% was attributable to revenue generated from operations in new markets. Same-market encounters increased 12.1%, same-market revenue increased 13.9% and same-market patient revenue per encounter increased 1.9%. The 1.9% increase was largely due to a combination of Medicare fee schedule rate increases and Medicaid parity. Medicaid parity represents an increase in Medicaid payments up to Medicare reimbursement levels for 2013 and 2014 in accordance with the Patient Protection and Affordable Care Act of 2010, as amended. Same-market areas are those geographic areas in which we have had operations for the entire current period and the entire comparable prior period. Because in-market area acquisitions are often small practice groups which become subsumed within our existing practice groups and are managed by our existing regional management staff, we consider these as part of our same-market area growth.

Physician practice salaries, benefits and other expenses increased by $17.0 million or 17.8% to $112.1 million, or 73.2% of net revenue, for the three months ended March 31, 2013 as compared to $95.1 million, or 73.3% of net revenue, for the same period in the prior year. The increase in practice costs is largely related to the increase in the number of hospitalists added through hiring and acquisitions during the period. Same-market area physician costs increased a total of $13.0 million, which was primarily the result of increased costs related to our new hires or acquired physician practices. In addition, $4.0 million of the $17.0 million overall cost increase is attributable to physician costs associated with our entrance into new markets.

General and administrative expenses include all salaries, benefits and operating expenses not specifically related to the day-to-day operations of our physician group practices, including billing and collections functions, our regional and market-area administrative offices and our corporate management and overhead. General and administrative expenses increased $3.7 million, or 18.7%, to $23.8 million, or 15.6% of net revenue, for the three months ended March 31, 2013, as compared to $20.1 million, or 15.5% of net revenue, for the same period in the prior year. The increase in expense was primarily the result of increased costs to support the continuing growth of our operations and acquisitions, including new regional office costs and other expenses. Excluding stock based compensation, general and administrative expenses were 14.4 % and 14.3% of revenue for the three months ended March 31, 2013 and 2012, respectively.

17

The net change in fair value of contingent consideration for acquisitions (“net change in fair value”) was a $1.1 million credit to expense and a $0.1 million increase to expense for the three months ended March 31, 2013 and 2012, respectively. Because the fair value of contingent consideration is generally based on a certain multiple of operating results of the acquired practices during a measurement period, a relatively small change in projected operating results can result in a large change to the fair value of such contingent consideration.

Income from operations increased $3.5 million, or 25.2%, to $17.1 million from $13.7 million for the same period in the prior year. Our operating margin was 11.2% and 10.5% for the three months ended March 31, 2013 and 2012, respectively. Excluding the net change in fair value, income from operations for the three months ended March 31, 2013 increased 16.5% to $16.0 million, or an operating margin of 10.5%, compared to income from operations of $13.8 million, or an operating margin of 10.6% for the same period in 2012.

Our effective tax rate for the three months ended March 31, 2013 was 38.3% compared to 37.5% for the three months ended March 31, 2012. The increase in the effective tax rate was primarily related to a change in state tax laws in November 2012. The effective tax rate differs from the statutory U.S. federal rate of 35.0% due primarily to state income taxes.

Net income for the three months ended March 31, 2013 increased to $10.5 million from $8.5 million for the three months ended March 31, 2012, and our net income margin was 6.9% for the three months ended March 31, 2013, as compared to 6.6% for the same period in the prior year. Earnings per share for the three months ended March 31, 2013 was $0.61 diluted earnings per share, compared to $0.50 diluted earnings per share for the same period in 2012. Excluding the net change in fair value, net income for the three months ended March 31, 2013 increased 14.9% to $9.8 million, or $0.57 diluted earnings per share, compared to net income of $8.6 million, or $0.51 diluted earnings per share for the same period in 2012.

Liquidity and Capital Resources

As of March 31, 2013, we had approximately $75.8 million in liquidity, which is composed of $21.0 million in cash and cash equivalents and an available line of credit of $54.8 million. We had borrowings of $20.0 million from our revolving line of credit outstanding at March 31, 2013. In April 2013, we repaid $7.5 million of our outstanding revolving line of credit.

Net cash provided by operating activities was $13.9 million and $14.9 million for the three months ended March 31, 2013 and 2012, respectively. The changes in working capital during the three months ended March 31, 2013 was largely related to an increase in accounts receivable of $12.1 million, a decrease in prepaid expenses and other current assets of $4.2 million, an increase in accrued compensation of $4.8 million primarily related to timing of payrolls and physician bonus payments, and an increase in accounts payable and accrued liabilities of $3.8 million.

Our days sales outstanding (DSO), which we use to measure the effectiveness of our collections, was 53 DSO as of March 31, 2013 as compared to 52 DSO as of December 31, 2012. We calculate our DSO using a three-month rolling average of net revenues.

Net cash used in investing activities was $10.8 million for the three months ended March 31, 2013, compared to $27.3 million for the same period in 2012. Cash of $9.7 million was used in the three months ended March 31, 2013 for physician practice acquisitions and contingent consideration payments on prior acquisitions, compared to $26.2 million in the same period of the prior year. The remainder of cash used in investing activities was for purchases of computer hardware and software, and office furnishings.

For the three months ended March 31, 2013, net cash provided by financing activities was $1.7 million, compared to $17.0 million provided by financing activities for the same period in 2012. In March 2012, we borrowed $15.0 million from our line of credit to fund new acquisitions and pay for contingent consideration related to acquired practices.

Credit Facility and Liquidity

Our secured revolving credit agreement (Credit Facility) provides a revolving line of credit of $75.0 million and contains an “accordion” feature that allows an increase of up to $25.0 million to the Credit Facility with lender approval. The Credit Facility has a maturity date of August 4, 2016 and is available for working capital, practice acquisitions, capital expenditures and general business expenses. As of March 31, 2013, we had borrowings of $20.0 million and letters of credit of $0.2 million outstanding, and $54.8 million available under the Credit Facility.

18

The revolving line of credit is limited by a formula based on a certain multiple times the trailing twelve months of earnings before interest, taxes, depreciation, amortization and certain non-cash items. Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.25%, or the lender’s prime rate plus 0% to 0.25%, both based on a leverage ratio. We pay an unused commitment fee equal to 0.25% per annum on the difference between the revolving line capacity and the average balance outstanding during the year. Outstanding amounts advanced to us under the revolving line of credit are repayable on or before the maturity date. The interest rate for our borrowings under the Credit Facility at March 31, 2013 was 1% per annum.

The Credit Facility is guaranteed by our subsidiaries and affiliated Professional Medical Corporations and limited liability companies, and is secured by substantially all of our and our guarantors’ tangible and intangible assets. The Credit Facility includes various customary financial covenants and restrictions, as well as customary remedies for our lenders following an event of default. As of March 31, 2013, we were in compliance with such financial covenants and restrictions.

We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Credit Facility will be sufficient to finance our working capital requirements and fund anticipated acquisitions, contingent acquisition consideration and capital expenditures.

Off Balance Sheet Arrangements

As of March 31, 2013, we had no off-balance sheet arrangements.

19

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to changes in interest rate as a result of our Credit Facility. At our option, the interest rate on outstanding borrowings under our Credit Facility is either LIBOR plus 0.75% to 1.25% or the lender’s prime rate plus 0% to 0.25%, both based on a leverage ratio. The lender’s prime rate is a daily floating rate most recently announced by our lender, whether or not such announced rate is the lowest rate available from our lender. LIBOR is either the 30, 60, 90 or 180 day LIBOR. Historically, we have chosen not to use interest rate derivatives to manage our exposure to changes in interest rates. We had long-term borrowings of $20 million bearing an annual interest of 1.0% under our Credit Facility at March 31, 2013. A 1.0% change in interest rate on our borrowings of $20 million would result in an impact to income before income taxes of approximately $200,000 on an annual basis.

Investments in both fixed rate and floating rate interest earning instruments carry a degree of interest rate risk. Fixed rate securities may have their fair market value adversely impacted due to a rise in interest rates, while floating rate securities with shorter maturities may produce less income if interest rates fall. As of March 31, 2013, all of our short-term investments were invested in money market funds with less than 90-day maturities and are classified as cash equivalents.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain controls and procedures designed to ensure that we are able to collect the information we are required to disclose in the reports we file with the Securities and Exchange Commission (SEC), and to process, summarize and disclose this information within the time periods specified in the rules of the SEC. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has conducted an evaluation of the design and operation of our “disclosure controls and procedures” as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting during the three months ended March 31, 2013 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

20

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Legal

In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated hospitalists. We may also become subject to other lawsuits, which could involve significant claims and/or significant defense costs.

We believe, based upon our review of pending actions and proceedings that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, or cash flows in a future period.

Government Inquiry

On June 7, 2010, we received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. See the discussion of the CID in Note 8 to the accompanying financial statements.

ITEMS 1A, 2, 3, 4 AND 5 ARE NOT APPLICABLE

ITEM 6. EXHIBITS

(a) Exhibits

Exhibits required by Item 601 of Regulation S-K are listed in the Exhibit Index on page 23 of this report.

21

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on the 30thday of April, 2013.

IPC THE HOSPITALIST COMPANY, INC.
By:	/S/    ADAM D. SINGER, M.D.
	Adam D. Singer, M.D. Chief Executive Officer
By:	/S/    RICK KLINE
	Rick Kline Chief Financial Officer

22

EXHIBIT INDEX

Exhibit Number	Description of Document
31.1	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes Oxley Act.
31.2	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes Oxley Act.
32.1	Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act.
32.2	Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

* Pursuant to Rule 406T of Regulation S-T, XBRL (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration statement or Prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

23

EX-31.1

Exhibit 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A)

OR RULE 15D-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT

I, Adam D. Singer, M.D., certify that:

1. I have reviewed this quarterly report on Form 10-Q of IPC The Hospitalist Company, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 30, 2013

/S/ ADAM D. SINGER, M.D.

Adam D. Singer, M.D.

Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A)

OR RULE 15D-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT

I, Rick Kline, certify that:

1. I have reviewed this quarterly report on Form 10-Q of IPC The Hospitalist Company, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 30, 2013

/S/ RICK KLINE

Rick Kline

Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of IPC The Hospitalist Company, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/S/ ADAM D. SINGER, M.D.

Adam D. Singer, M.D.

Chief Executive Officer

Date: April 30, 2013

EX-32.2

Exhibit 32.2

CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of IPC The Hospitalist Company, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/S/ RICK KLINE

Rick Kline

Chief Financial Officer

Date: April 30, 2013

XML

Earnings Per Share - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2013
Earnings Per Share [Abstract]
Stock options excluded from diluted shares computation	614,000

XML

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized When Options, Restricted Stock Awards, Performance Stock Awards and Employee Stock Purchase Plan Shares Vested (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Compensation Related Costs [Abstract]
Stock-based compensation expense	$ 1,735	$ 1,464

XML

Practice Acquisitions - Schedule of Acquisition of Hospitalist Practices (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013
Acquired assets - paid and accrued:
Goodwill - 2013 transactions	$ 6,886
Other intangible assets	110
Fixed assets	15
Total acquired assets - 2013	7,011
Goodwill - adjustment for prior year transactions	(2,059)
Total acquired assets	4,952
Cash paid for acquisitions:
2013 transactions	(5,700)
Contingent consideration	(3,918)
Other - prior year transactions	(73)
Total cash paid for acquisitions	(9,691)
Decrease in payable for practice acquisitions	(4,739)
Net change in fair value of contingent consideration	(1,093)
Net change in payable for practice acquisitions	(5,832)
Payable for practice acquisitions, beginning of period	29,038
Payable for practice acquisitions, end of period	$ 23,206

XML

Stock-Based Compensation - Summary of Restricted Stock Awards and Performance Stock Awards Activities in Equity Plan (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares, Restricted stock awards outstanding as of December 31, 2012	101,940
Shares, Granted	124,642
Shares, Released	(10,432)
Shares, Restricted stock awards outstanding as of March 31, 2013	216,150
Weighted-Average Remaining Contractual Term, Restricted stock awards outstanding as of March 31, 2013 (Years)	2 years 11 days
Aggregate Intrinsic Value, Restricted stock awards outstanding as of March 31, 2013	$ 8,306
Weighted-Average Fair Value, Restricted stock awards outstanding as of December 31, 2012	$ 38.03
Weighted-Average Fair Value, Granted	$ 42.04
Weighted-Average Fair Value, Released	$ 39.33
Weighted-Average Fair Value, Restricted stock awards outstanding as of March 31, 2013	$ 40.28

XML

Debt

3 Months Ended

Mar. 31, 2013

Debt Disclosure [Abstract]

Debt

Note 4. Debt

Our secured revolving credit agreement (Credit Facility) provides a revolving line of credit of $75.0 million and contains an “accordion” feature that allows an increase of up to $25.0 million to the Credit Facility with lender approval. The Credit Facility has a maturity date of August 4, 2016 and is available for working capital, practice acquisitions, capital expenditures and general business expenses. As of March 31, 2013, we had long-term borrowings of $20.0 million and letters of credit of $0.2 million outstanding, and $54.8 million available under the Credit Facility.

The revolving line of credit is limited by a formula based on a certain multiple times the trailing twelve months of earnings before interest, taxes, depreciation, amortization and certain non-cash items. Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.25%, or the lender’s prime rate plus 0% to 0.25%, both based on a leverage ratio. We pay an unused commitment fee equal to 0.25% per annum on the difference between the revolving line capacity and the average balance outstanding during the year. Outstanding amounts advanced to us under the revolving line of credit are repayable on or before the maturity date. The interest rate for our borrowings under the Credit Facility at March 31, 2013 was 1% per annum.

The Credit Facility is guaranteed by our subsidiaries and affiliated Professional Medical Corporations and limited liability companies, and is secured by substantially all of our and our guarantors’ tangible and intangible assets. The Credit Facility includes various customary financial covenants and restrictions, as well as customary remedies for our lenders following an event of default. As of March 31, 2013, we were in compliance with such financial covenants and restrictions.

XML

Debt - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2013
Line of Credit Facility [Line Items]
Amount provided by credit agreement	$ 20.0
Letters of credit amount outstanding	0.2
Remaining amount available under revolving line of credit	54.8
Interest rate terms	Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.25%, or the lender's prime rate plus 0% to 0.25%, both based on a leverage ratio
Percentage of unused commitment fee, per annum	0.25%
Revolving line of credit interest rate, per annum	1.00%
Secured revolving credit agreement (Credit Facility) [Member]
Line of Credit Facility [Line Items]
Revolving line of credit borrowing capacity	75.0
Additional borrowing capacity under revolving line of credit	$ 25.0
Maturity date of Credit Facility	Aug. 04, 2016
LIBOR [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate	0.75%
LIBOR [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate	1.25%
Lender's prime rate [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate	0.00%
Lender's prime rate [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate	0.25%

XML

Fair Value Measurement - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2013	Dec. 31, 2012
Fair Value Disclosures [Abstract]
Payable for practice	$ 23,206,000	$ 29,038,000
Business acquisition, contingent consideration, payables	22,975,000
Business acquisition, liabilities recorded at undiscounted carrying value	$ 231,000
Discount rate on significant inputs	2.60%
Probability of achieving estimated projected earnings	100.00%

XML

Income Taxes - Schedule of Income Tax Provisions and Effective Tax Rates (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Income Tax Disclosure [Abstract]
Income tax provision	$ 6,521	$ 5,105
Effective tax rate	38.30%	37.50%

XML

Income Taxes - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2013
Income Tax Disclosure [Abstract]
Statutory U.S. federal income tax rate	35.00%

XML

Fair Value Measurement

3 Months Ended

Mar. 31, 2013

Fair Value Disclosures [Abstract]

Fair Value Measurement

Note 3. Fair Value Measurement

Some of our liabilities are measured and recorded at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The established fair value hierarchy distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (Levels 1 and 2) and the reporting entity’s own assumptions about market participant assumptions (Level 3). This hierarchy is used to measure fair value as follows:

• Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities.

• Level 2 inputs include quoted prices for similar assets and liabilities in active markets; quoted prices in markets that are not active; and other inputs that are observable or can be corroborated by observable market data for the asset or liability.

• Level 3 inputs are unobservable inputs for the asset or liability that are supported by little or no market activity.

The following table presents our liabilities measured at fair value on a recurring basis as of March 31, 2013 (in thousands):

	Quoted Price In Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Balance
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	$	0	$	0	$	22,975	$	22,975

The following table presents a rollforward of our liabilities measured at fair value on a recurring basis using significant unobservable inputs (level 3) for the three months ended March 31, 2013 (in thousands):

	Three Months Ended March 31, 2013
Accrued contingent consideration for practice acquisitions
Beginning balance	$	28,834
Addition through acquisition transactions		1,211
Adjustment for prior year transactions		(2,059	)
Change in fair value realized		(1,093	)
Payments		(3,918	)
Ending balance	$	22,975

Our payable for practice acquisitions totaling $23,206,000 at March 31, 2013 is composed of $22,975,000 of accrued contingent consideration measured at fair value, and $231,000 of other practice acquisition liabilities recorded at undiscounted carrying value which approximates fair value. The fair value of our accrued contingent consideration is determined using widely accepted valuation techniques, which include the income approach for estimating future consideration to be paid based on projected earnings of our acquired practices as of specified measurement dates. The income approach involves the use of a probability-weighted discounted cash flow model based on significant inputs not observable in the market. The significant inputs include a discount rate of 2.6%, and 100% probability of achieving the estimated projected earnings.

Because our accrued contingent consideration is generally based on a certain multiple of earnings of the acquired practices during a specified measurement period, a relatively small change in such projected earnings may result in a material change to the fair value of such contingent consideration liability with a corresponding adjustment to income from operations. We reassess our projected earnings and the related fair value of our accrued contingent consideration for practice acquisitions on a quarterly basis.

XML

Stock-Based Compensation - Additional Information (Detail)			3 Months Ended
	Mar. 31, 2013	Jun. 07, 2012	Mar. 31, 2013 Stock options [Member]	Mar. 31, 2013 Restricted stock awards [Member]	Mar. 31, 2013 Performance stock awards [Member] Minimum [Member]	Mar. 31, 2013 Performance stock awards [Member] Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares reserved for issuance under stock-based employee compensation program	4,943,170
Common stock available for issuance under equity plan	1,132,018	1,422,130
Vesting period, in years			4 years	4 years	2 years	3 years

XML

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 21,007	$ 16,214
Accounts receivable, net	91,748	79,612
Insurance receivable for malpractice claims - current portion	10,437	9,719
Prepaid expenses and other current assets	13,036	17,284
Total current assets	136,228	122,829
Property and equipment, net	6,073	5,763
Goodwill	244,836	240,009
Other intangible assets, net	1,907	2,133
Deferred tax assets, net	250	250
Insurance receivable for malpractice claims - less current portion	18,338	17,074
Total assets	407,632	388,058
Current liabilities:
Accounts payable and accrued liabilities	8,096	4,257
Accrued compensation	33,411	28,615
Payable for practice acquisitions	23,206	29,038
Medical malpractice and self-insurance reserves, current portion	11,090	10,350
Deferred tax liabilities	1,506	1,506
Total current liabilities	77,309	73,766
Long-term debt	20,000	20,000
Medical malpractice and self-insurance reserves, less current portion	40,062	37,921
Total liabilities	137,371	131,687
Stockholders' equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued	0	0
Common stock, $0.001 par value, 50,000,000 shares authorized, 16,753,021 and 16,694,215 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively	17	17
Additional paid-in capital	154,096	150,711
Retained earnings	116,148	105,643
Total stockholders' equity	270,261	256,371
Total liabilities and stockholders' equity	$ 407,632	$ 388,058

XML

Basis of Presentation and Significant Accounting Policies

3 Months Ended

Mar. 31, 2013

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies

Note 1. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

IPC The Hospitalist Company, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time hospitalist practices. We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. The consolidated financial statements include all accounts of IPC The Hospitalist Company, Inc. and its wholly owned subsidiaries and consolidated professional medical corporations (Professional Medical Corporations) managed under long-term management agreements.

Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have controls over the operations of these VIE’s. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.

In our opinion, these consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to GAAP and SEC rules and regulations, which are applicable to interim financial statements. As a result, the following disclosures should be read in conjunction with our audited consolidated financial statements and notes thereto as of December 31, 2012 included in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC on February 26, 2013.

Revenue

Net revenue consists of fees for medical services provided by our affiliated hospitalists under fee-for-service, case rate and other professional fee arrangements with various payors including Medicare, Medicaid, managed care organizations, insurance companies and hospitals. Net revenue is reported in the period in which services are provided at amounts expected to be collected, which excludes contractual discounts and an estimate of uncollectible accounts.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. The process of estimating these assets and liabilities involves judgment decisions, which are subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2013.

Fair Value of Financial Instruments

Our consolidated balance sheets as of March 31, 2013 and December 31, 2012 included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit in December 2012 approximated its fair value at March 31, 2013 and December 31, 2012. Pursuant to GAAP, we determine the fair value of our long-term borrowing using quoted market prices, which is defined as Level 2 input under GAAP on fair value measures.

Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions, which is carried at fair value determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. The remaining amount of our payable for practice acquisitions is recorded at its carrying value, which approximates its fair value due to the relatively short period of time between its origination and its expected realization. See Note 3 for more information.

Goodwill

The changes in the carrying amount of goodwill for the three months ended March 31, 2013 are as follows (in thousands):

Goodwill - beginning balance at January 1, 2013	$	240,009
Goodwill acquired during 2013		6,886
Adjustment for prior year transactions		(2,059	)
Goodwill - ending balance at March 31, 2013	$	244,836

The valuation studies related to the practice acquisitions that occurred in the fourth quarter of 2012 have been completed, and as a result, the related valuations as of the acquisition dates have been reduced by $2,059,000, which is reflected in the above table.

Medical Malpractice Liability Insurance

We record our medical malpractice reserves, on an undiscounted basis, for claims incurred and reported and claims incurred but not reported (IBNR) during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP. Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):

	March 31, 2013								December 31, 2012
	Assets		Liabilities						Assets		Liabilities
	Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities		Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities
Current Portion	$	10,437	$	10,488		602		11,090	$	9,719	$	9,846		504		10,350
Long-term Portion		18,338		18,338		21,724		40,062		17,074		17,074		20,847		37,921
Total	$	28,775	$	28,826		22,326		51,152	$	26,793	$	26,920		21,351		48,271

XML

Stock-Based Compensation - Schedule of Fair Value of Each Option Grant Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Detail)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rate	0.66%	1.21%
Expected volatility	40.09%	39.86%
Expected option life (in years)	4 years 5 months 1 day	6 years 1 month 28 days
Expected dividend yield	0.00%	0.00%

XML

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013
Business Combinations [Abstract]
Adjustment for prior year transactions	$ 2,059

XML

Stock-Based Compensation - Summary of Activity in Equity Plan (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares, Options outstanding as of December 31, 2012	1,630,921
Shares, Granted	44,468
Shares, Exercised	(30,252)
Shares, Cancelled/Forfeited	0
Shares, Expired	(26)
Shares, Options outstanding as of March 31, 2013	1,645,111
Shares, Options exercisable as of March 31, 2013	1,191,721
Weighted-Average Exercise Price, Options outstanding as of December 31, 2012	$ 28.36
Weighted-Average Exercise Price, Granted	$ 41.55
Weighted-Average Exercise Price, Exercised	$ 12.03
Weighted-Average Exercise Price, Cancelled/Forfeited
Weighted-Average Exercise Price, Expired	$ 1.60
Weighted-Average Exercise Price, Options outstanding as of March 31, 2013	$ 29.02
Weighted-Average Exercise Price, Options exercisable as of March 31, 2013	$ 24.90
Weighted-Average Remaining Contractual Term, Options outstanding as of March 31, 2013 (Years)	6 years 9 months
Weighted-Average Remaining Contractual Term, Options exercisable as of March 31, 2013 (Years)	6 years 3 months 7 days
Aggregate Intrinsic Value, Options outstanding as of as of March 31, 2013	$ 25,936
Aggregate Intrinsic Value, Options exercisable as of March 31, 2013	$ 23,607
Weighted-Average Fair Value, Options outstanding as of December 31, 2012	$ 11.95
Weighted-Average Fair Value, Granted	$ 13.97
Weighted-Average Fair Value, Exercised	$ 4.67
Weighted-Average Fair Value, Cancelled/Forfeited
Weighted-Average Fair Value, Expired	$ 6.83
Weighted-Average Fair Value, Options outstanding as of March 31, 2013	$ 12.13
Weighted-Average Fair Value, Options exercisable as of March 31, 2013	$ 7.61

XML

Practice Acquisitions - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2013 Hospitalist
Business Combinations [Abstract]
Number of hospitalist physician practices acquired	2
Period in which identifiable intangible assets amortized for tax purposes, years	15 years

XML

Practice Acquisitions

3 Months Ended

Mar. 31, 2013

Business Combinations [Abstract]

Practice Acquisitions

Note 2. Practice Acquisitions

We recognize all of the assets acquired, liabilities assumed and any contingent consideration at the acquisition-date fair value and expense all transaction related costs.

During the three months ended March 31, 2013, in connection with the acquisition of assets of two hospitalist physician practices, we recorded goodwill and other identifiable intangible assets consisting of physician and hospital agreements. Amounts recorded as goodwill and identifiable intangible assets are not amortizable for GAAP financial reporting purpose but are amortized for tax purposes over 15 years. The results of operations of these acquisitions are included in the consolidated financial statements from the respective dates of acquisition.

In addition to the initial consideration paid at the close of each transaction, the asset purchase agreements for the two acquisitions completed during the three months ended March 31, 2013 provide for contingent consideration to be paid, which is generally based upon the achievement of certain operating results of the acquired practices as of certain measurement dates. These additional payments are not contingent upon the future employment of the sellers. The contingent consideration for these acquisitions was recorded on a provisional basis pending completion of the valuation studies as of the acquisition dates.

We estimate the fair value of contingent consideration to be paid based on discounted projected earnings of the acquired practices as of certain measurement dates. The discount rate that we use consists of a risk-free U.S. Treasury bond yield plus a Company specific credit spread which we believe is acceptable by willing market participants.

The following table summarizes the total amounts recorded during the three months ended March 31, 2013, related to the acquisition of hospitalist practices (in thousands):

Acquired assets - paid and accrued:
Goodwill - 2013 transactions	$	6,886
Other intangible assets		110
Fixed assets		15
Total acquired assets - 2013		7,011
Goodwill - adjustment for prior year transactions		(2,059	)
		4,952
Cash paid for acquisitions:
2013 transactions		(5,700	)
Contingent consideration		(3,918	)
Other - prior year transactions		(73	)
Total cash paid for acquisitions		(9,691	)
Decrease in payable for practice acquisitions		(4,739	)
Net change in fair value of contingent consideration		(1,093	)
Net change in payable for practice acquisitions		(5,832	)
Payable for practice acquisitions, beginning of period		29,038
Payable for practice acquisitions, end of period	$	23,206

XML

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	15,000,000	15,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	16,753,021	16,694,215
Common stock, shares outstanding	16,753,021	16,694,215

XML

Fair Value Measurement (Tables)

3 Months Ended

Mar. 31, 2013

Fair Value Disclosures [Abstract]

Liabilities Measured at Fair Value on Recurring Basis

The following table presents our liabilities measured at fair value on a recurring basis as of March 31, 2013 (in thousands):

	Quoted Price In Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Balance
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	$	0	$	0	$	22,975	$	22,975

Rollforward for Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs

The following table presents a rollforward of our liabilities measured at fair value on a recurring basis using significant unobservable inputs (level 3) for the three months ended March 31, 2013 (in thousands):

	Three Months Ended March 31, 2013
Accrued contingent consideration for practice acquisitions
Beginning balance	$	28,834
Addition through acquisition transactions		1,211
Adjustment for prior year transactions		(2,059	)
Change in fair value realized		(1,093	)
Payments		(3,918	)
Ending balance	$	22,975

XML

Document and Entity Information	3 Months Ended
	Mar. 31, 2013	Apr. 23, 2013
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q1
Trading Symbol	IPCM
Entity Registrant Name	IPC The Hospitalist Company, Inc.
Entity Central Index Key	0001410471
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		16,765,161

XML

Income Taxes (Tables)

3 Months Ended

Mar. 31, 2013

Income Tax Disclosure [Abstract]

Schedule of Income Tax Provisions and Effective Tax Rates

Following are the income tax provisions and effective tax rates for the three months ended March 31, 2013 and 2012 (dollars in thousands):

	Three Months Ended March 31,
	2013			2012
Income tax provision	$	6,521		$	5,105
Effective tax rate		38.3	%		37.5	%

XML

Consolidated Statements of Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Income Statement [Abstract]
Net revenue	$ 153,091	$ 129,793
Operating expenses:
Cost of services - physician practice salaries, benefits and other	112,068	95,098
General and administrative	23,823	20,074
Net change in fair value of contingent consideration	(1,093)	84
Depreciation and amortization	1,154	848
Total operating expenses	135,952	116,104
Income from operations	17,139	13,689
Investment income	2	4
Interest expense	(115)	(82)
Income before income taxes	17,026	13,611
Income tax provision	6,521	5,105
Net income	$ 10,505	$ 8,506
Net income per share:
Basic	$ 0.63	$ 0.52
Diluted	$ 0.61	$ 0.50

XML

Earnings Per Share

3 Months Ended

Mar. 31, 2013

Earnings Per Share [Abstract]

Earnings Per Share

Note 7. Earnings Per Share

Basic net income per share is calculated by dividing net income for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing net income for the period by the weighted average number of shares outstanding during the period plus the dilutive effect of our outstanding stock awards and shares issuable under our employee stock purchase plan using the treasury stock method.

The calculations of basic and diluted net income per share for the three months ended March 31, 2013 and 2012 are as follows (dollars in thousands, except for per share data):

	Three Months Ended March 31,
	2013		2012
Basic:
Net income	$	10,505	$	8,506
Weighted average number of common shares outstanding		16,703,369		16,505,047
Basic net income per share	$	0.63	$	0.52
Diluted:
Net income	$	10,505	$	8,506
Weighted average number of common shares outstanding		16,703,369		16,505,047
Weighted average number of dilutive common shares equivalents from stock options		422,571		355,608
Common shares and common share equivalents		17,125,940		16,860,655
Diluted net income per share	$	0.61	$	0.50

As of March 31, 2013, 614,000 outstanding stock options are excluded from our diluted computation because their exercise option price is above market, or they are anti-dilutive under the treasury stock method.

XML

Stock-Based Compensation

3 Months Ended

Mar. 31, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

Note 6. Stock-Based Compensation

At March 31, 2013, we had a stock-based employee compensation program, for which we had reserved a total of 4,943,170 common shares for issuance. Under our 2012 Equity Participation Plan (Equity Plan), which was approved by our stockholders on June 7, 2012, a total of 1,422,130 shares of our common stock are available for issuance and no new awards will be issued under any previous equity participation plans. As of March 31, 2013, there were 1,132,018 shares of our common stock available for future grants under our Equity Plan, which included the canceled and forfeited shares issued under previous equity participation plans.

All option awards granted during the three months ended March 31, 2013 were issued with exercise prices equal to the closing price of our common stock on the NASDAQ Global Select Market on the dates of the grant. The options under the Equity Plan generally vest over a four-year period from date of grant, and unrestricted options terminate on the 10th anniversary of the agreement date for all grants issued before January 1, 2013 and on the 7th anniversary of the agreement date for all grants issued after December 31, 2012. Restricted stock awards generally vest over a four-year period from date of the award and performance stock awards generally vest over two to three years from date of the award.

Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):

	Three months ended March 31,
	2013		2012
Stock-based compensation expense	$	1,735	$	1,464

As of March 31, 2013, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and previous equity participation plans and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands).

	Total Unrecognized Compensation Cost		Weighted-average Remaining Contractual Term
			(Years)
Stock option	$	7,173		6.75
Restricted/Performance stock	$	7,241		2.03

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions:

	Three months ended March 31,
	2013			2012
Risk-free interest rate		0.66	%		1.21	%
Expected volatility		40.09	%		39.86	%
Expected option life (in years)		4.42			6.16
Expected dividend yield		0.00	%		0.00	%

The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero coupon issues. The expected volatility is based on historical volatility levels of our public company peer group and the volatility of our stock price since our initial public offering in January 2008. The expected option life of each award granted was calculated using the “simplified method” in accordance with GAAP.

The grant date fair value of each restricted stock award or performance stock award is based on the closing stock price on the grant date of the award as reported by NASDAQ Global Select Market.

The following table summarizes the stock option activities in our Equity Plan during the three months ended March 31, 2013.

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value		Weighted- Average Fair Value
						(Years)		(in 000s)
Options outstanding as of December 31, 2012		1,630,921		$	28.36					$	11.95
Changes during period:
Granted		44,468			41.55						13.97
Exercised		(30,252	)		12.03						4.67
Cancelled/Forfeited		0			—						—
Expired		(26	)		1.60						6.83
Options outstanding as of March 31, 2013		1,645,111		$	29.02		6.75	$	25,936	$	12.13
Options exercisable as of March 31, 2013		1,191,721		$	24.90		6.27	$	23,607	$	7.61

The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the three months ended March 31, 2013.

	Shares			Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value		Weighted- Average Fair Value
				(Years)		(in 000s)
Restricted/performance stock awards outstanding as of December 31, 2012		101,940						$	38.03
Changes during period:
Granted		124,642							42.04
Released		(10,432	)						39.33
Restricted/performance stock awards outstanding as of March 31, 2013		216,150			2.03	$	8,306	$	40.28

XML

Basis of Presentation and Significant Accounting Policies - Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Health Care Organizations [Abstract]
Insurance Receivable, Current Portion	$ 10,437	$ 9,719
Insurance Receivable, Long-term Portion	18,338	17,074
Insurance Receivable, Total	28,775	26,793
Claims Reserve, Current Portion	10,488	9,846
Claims Reserve, Long-term Portion	18,338	17,074
Claims Reserve, Total	28,826	26,920
IBNR Reserve, Current Portion	602	504
IBNR Reserve, Long-term Portion	21,724	20,847
IBNR Reserve, Total	22,326	21,351
Total Liabilities, Current Portion	11,090	10,350
Total Liabilities, Long-term Portion	40,062	37,921
Total Liabilities	$ 51,152	$ 48,271

XML

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Stock-Based Compensation Expense Recognized When Options, Restricted Stock Awards, Performance Stock Awards and Employee Stock Purchase Plan Shares Vested

Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):

	Three months ended March 31,
	2013		2012
Stock-based compensation expense	$	1,735	$	1,464

Schedule of Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements Granted under Equity Plan and Previous Equity Participation Plans and Weighted-Average Period of Years Expected to Recognize Those Costs

As of March 31, 2013, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and previous equity participation plans and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands).

	Total Unrecognized Compensation Cost		Weighted-average Remaining Contractual Term
			(Years)
Stock option	$	7,173		6.75
Restricted/Performance stock	$	7,241		2.03

Schedule of Fair Value of Each Option Grant Estimated on Date of Grant Using Black-Scholes Option-Pricing Model

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions:

	Three months ended March 31,
	2013			2012
Risk-free interest rate		0.66	%		1.21	%
Expected volatility		40.09	%		39.86	%
Expected option life (in years)		4.42			6.16
Expected dividend yield		0.00	%		0.00	%

Summary of Activity in Equity Plan

The following table summarizes the stock option activities in our Equity Plan during the three months ended March 31, 2013.

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value		Weighted- Average Fair Value
						(Years)		(in ,000s)
Options outstanding as of December 31, 2012		1,630,921		$	28.36					$	11.95
Changes during period:
Granted		44,468			41.55						13.97
Exercised		(30,252	)		12.03						4.67
Cancelled/Forfeited		0			—						—
Expired		(26	)		1.60						6.83
Options outstanding as of March 31, 2013		1,645,111		$	29.02		6.75	$	25,936	$	12.13
Options exercisable as of March 31, 2013		1,191,721		$	24.90		6.27	$	23,607	$	7.61

Summary of Restricted Stock Awards and Performance Stock Awards Activities in Equity Plan

The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the three months ended March 31, 2013.

	Shares			Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value		Weighted- Average Fair Value
				(Years)		(in ,000s)
Restricted/performance stock awards outstanding as of December 31, 2012		101,940						$	38.03
Changes during period:
Granted		124,642							42.04
Released		(10,432	)						39.33
Restricted/performance stock awards outstanding as of March 31, 2013		216,150			2.03	$	8,306	$	40.28

XML

Basis of Presentation and Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2013

Accounting Policies [Abstract]

Schedule of Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill for the three months ended March 31, 2013 are as follows (in thousands):

Goodwill - beginning balance at January 1, 2013	$	240,009
Goodwill acquired during 2013		6,886
Adjustment for prior year transactions		(2,059	)
Goodwill - ending balance at March 31, 2013	$	244,836

Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables

Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):

	March 31, 2013								December 31, 2012
	Assets		Liabilities						Assets		Liabilities
	Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities		Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities
Current Portion	$	10,437	$	10,488		602		11,090	$	9,719	$	9,846		504		10,350
Long-term Portion		18,338		18,338		21,724		40,062		17,074		17,074		20,847		37,921
Total	$	28,775	$	28,826		22,326		51,152	$	26,793	$	26,920		21,351		48,271

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2013

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 8. Commitments and Contingencies

Legal

In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated hospitalists. We may also become subject to other lawsuits, which could involve significant claims and/or significant defense costs.

We believe, based upon our review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, or cash flows in a future period.

Government Inquiry

On June 7, 2010, we received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. The CID requested information concerning claims that we have submitted to Medicare and Medicaid. The CID covered the period from January 1, 2003, through June 4, 2010, and requested production of a range of documents relating to our Medicare and Medicaid participation, physician arrangements, operations, billings and compliance programs. We believe we have a strong compliance focus, and that we operate with appropriate billing policies, procedures, provider training, and compliance programs and controls. We have produced responsive documents, will discuss with representatives of the government additional future productions to be made if requested and will continue to cooperate in the government investigation. We have been informed by the DOJ that a qui tam whistleblower complaint related to this investigation naming the Company has been filed under court seal in the U.S. District Court for the Northern District of Illinois (Chicago). We also have been informed that several state attorneys general are examining our Medicaid claims in coordination with the DOJ. It is not possible to predict whether or when this matter may be resolved or what impact, if any, the outcome of this matter might have on our consolidated financial position, results of operations, or cash flows.

XML

Basis of Presentation and Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2013

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

IPC The Hospitalist Company, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time hospitalist practices. We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. The consolidated financial statements include all accounts of IPC The Hospitalist Company, Inc. and its wholly owned subsidiaries and consolidated professional medical corporations (Professional Medical Corporations) managed under long-term management agreements.

Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have controls over the operations of these VIE’s. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.

In our opinion, these consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to GAAP and SEC rules and regulations, which are applicable to interim financial statements. As a result, the following disclosures should be read in conjunction with our audited consolidated financial statements and notes thereto as of December 31, 2012 included in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC on February 26, 2013.

Revenue

Revenue

Net revenue consists of fees for medical services provided by our affiliated hospitalists under fee-for-service, case rate and other professional fee arrangements with various payors including Medicare, Medicaid, managed care organizations, insurance companies, and hospitals. Net revenue is reported in the period in which services are provided at amounts expected to be collected, which excludes contractual discounts and an estimate of uncollectible accounts

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. The process of estimating these assets and liabilities involves judgment decisions, which are subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2013.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Our consolidated balance sheets as of March 31, 2013 and December 31, 2012 included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit in December 2012 approximated its fair value at March 31, 2013 and December 31, 2012. Pursuant to GAAP, we determine the fair value of our long-term borrowing using quoted market prices, which is defined as Level 2 input under GAAP on fair value measures.

Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions, which is carried at fair value determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. The remaining amount of our payable for practice acquisitions is recorded at its carrying value, which approximates its fair value due to the relatively short period of time between its origination and its expected realization. See Note 3 for more information.

Goodwill

Goodwill

The changes in the carrying amount of goodwill for the three months ended March 31, 2013 are as follows (in thousands):

Goodwill - beginning balance at January 1, 2013	$	240,009
Goodwill acquired during 2013		6,886
Adjustment for prior year transactions		(2,059	)
Goodwill - ending balance at March 31, 2013	$	244,836

The valuation studies related to the practice acquisitions that occurred in the fourth quarter of 2012 have been completed, and as a result, the related valuations as of the acquisition dates have been reduced by $2,059,000, which is reflected in the above table.

Medical Malpractice Liability Insurance

Medical Malpractice Liability Insurance

We record our medical malpractice reserves, on an undiscounted basis, for claims incurred and reported and claims incurred but not reported (IBNR) during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP. Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):

	March 31, 2013								December 31, 2012
	Assets		Liabilities						Assets		Liabilities
	Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities		Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities
Current Portion	$	10,437	$	10,488		602		11,090	$	9,719	$	9,846		504		10,350
Long-term Portion		18,338		18,338		21,724		40,062		17,074		17,074		20,847		37,921
Total	$	28,775	$	28,826		22,326		51,152	$	26,793	$	26,920		21,351		48,271

XML

Practice Acquisitions (Tables)

3 Months Ended

Mar. 31, 2013

Business Combinations [Abstract]

Schedule of Acquisition of Hospitalist Practices

The following table summarizes the total amounts recorded during the three months ended March 31, 2013, related to the acquisition of hospitalist practices (in thousands):

Acquired assets - paid and accrued:
Goodwill - 2013 transactions	$	6,886
Other intangible assets		110
Fixed assets		15
Total acquired assets - 2013		7,011
Goodwill - adjustment for prior year transactions		(2,059	)
		4,952
Cash paid for acquisitions:
2013 transactions		(5,700	)
Contingent consideration		(3,918	)
Other - prior year transactions		(73	)
Total cash paid for acquisitions		(9,691	)
Decrease in payable for practice acquisitions		(4,739	)
Net change in fair value of contingent consideration		(1,093	)
Net change in payable for practice acquisitions		(5,832	)
Payable for practice acquisitions, beginning of period		29,038
Payable for practice acquisitions, end of period	$	23,206

XML

Stock-Based Compensation - Schedule of Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements Granted under Equity Plan and Previous Equity Participation Plans and Weighted-Average Period of Years Expected to Recognize Those Costs (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Unrecognized Compensation Cost	$ 7,173
Weighted-average Remaining Contractual Term (Years)	6 years 9 months
Restricted/Performance stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Unrecognized Compensation Cost	$ 7,241
Weighted-average Remaining Contractual Term (Years)	2 years 11 days

XML

Basis of Presentation and Significant Accounting Policies - Schedule of Changes in Carrying Amount of Goodwill (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013
Business Combinations [Abstract]
Goodwill - beginning balance	$ 240,009
Goodwill acquired during 2013	6,886
Adjustment for prior year transactions	(2,059)
Goodwill - ending balance	$ 244,836

XML

Fair Value Measurement - Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013
Fair Value Assets Measured On Recurring Basis [Line Items]
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	$ 22,975
Quoted Price In Active Markets for Identical Instruments (Level 1) [Member]
Fair Value Assets Measured On Recurring Basis [Line Items]
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	0
Significant Other Observable Inputs (Level 2) [Member]
Fair Value Assets Measured On Recurring Basis [Line Items]
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Assets Measured On Recurring Basis [Line Items]
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	$ 22,975

XML

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Operating activities
Net income	$ 10,505	$ 8,506
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,154	848
Stock-based compensation expense	1,735	1,464
Net change in fair value of contingent consideration	(1,093)	84
Changes in assets and liabilities:
Accounts receivable	(12,136)	(8,198)
Prepaid expenses and other current assets	4,248	2,725
Accounts payable and accrued liabilities	3,839	3,006
Accrued compensation	4,796	5,584
Medical malpractice and self-insurance reserves, net	899	913
Net cash provided by operating activities	13,947	14,932
Investing activities
Acquisitions of physician practices	(9,691)	(26,222)
Purchase of property and equipment	(1,113)	(1,105)
Net cash used in investing activities	(10,804)	(27,327)
Financing activities
Proceeds from long-term debt	0	15,000
Net proceeds from issuance of common stock	1,333	1,777
Excess tax benefits from stock-based compensation	317	186
Net cash provided by financing activities	1,650	16,963
Net increase in cash and cash equivalents	4,793	4,568
Cash and cash equivalents, beginning of period	16,214	17,752
Cash and cash equivalents, end of period	21,007	22,320
Cash paid for:
Interest	75	31
Income taxes	$ 490	$ 627

XML

Income Taxes

3 Months Ended

Mar. 31, 2013

Income Tax Disclosure [Abstract]

Income Taxes

Note 5. Income Taxes

Following are the income tax provisions and effective tax rates for the three months ended March 31, 2013 and 2012 (dollars in thousands):

	Three Months Ended March 31,
	2013			2012
Income tax provision	$	6,521		$	5,105
Effective tax rate		38.3	%		37.5	%

The increase in the effective tax rate during 2013 as compared to the same period of 2012 was primarily related to a change in state tax laws in November 2012. The effective tax rates differ from the statutory U.S. federal income tax rate of 35.0% due primarily to state income taxes.

Our accounting policy is to include interest and penalties related to income tax liabilities in income tax expense. As of March 31, 2013, we did not have any estimated interest and penalties related to uncertain tax positions.

The tax years 2008 to 2011 remain open to examination by the major taxing jurisdictions to which we are subject. The statute of limitations for tax years 1999 to 2007 has expired, except that the tax year 1999 is subject to adjustment of net operating losses by the Internal Revenue Service. We are subject to taxation in the United States and various state jurisdictions. One federal examination has been initiated for our company and subsidiaries and one state examination has been initiated for one of our subsidiaries. The outcome of such examination cannot be predicted with certainty; however, we believe that the ultimate resolution will not have a material effect on our financial position, results of operations or cash flows.

We make our best estimate of the tax rate expected to be applicable for the full fiscal year. The rate so determined is used to compute our income tax expense for an interim period.

XML

Fair Value Measurement - Rollforward for Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013
Fair Value Disclosures [Abstract]
Beginning balance	$ 28,834
Addition through acquisition transactions	1,211
Adjustment for prior year transactions	(2,059)
Change in fair value realized	(1,093)
Payments	(3,918)
Ending balance	$ 22,975

XML

Earnings Per Share - Schedule of Basic and Diluted Net Income Per Share (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Basic:
Net income	$ 10,505	$ 8,506
Weighted average number of common shares outstanding	16,703,369	16,505,047
Basic net income per share	$ 0.63	$ 0.52
Diluted:
Net income	$ 10,505	$ 8,506
Weighted average number of common shares outstanding	16,703,369	16,505,047
Weighted average number of dilutive common shares equivalents from stock options	422,571	355,608
Common shares and common share equivalents	17,125,940	16,860,655
Diluted net income per share	$ 0.61	$ 0.50

XML

Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2013

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Income Per Share

The calculations of basic and diluted net income per share for the three months ended March 31, 2013 and 2012 are as follows (dollars in thousands, except for per share data):

	Three Months Ended March 31,
	2013		2012
Basic:
Net income	$	10,505	$	8,506
Weighted average number of common shares outstanding		16,703,369		16,505,047
Basic net income per share	$	0.63	$	0.52
Diluted:
Net income	$	10,505	$	8,506
Weighted average number of common shares outstanding		16,703,369		16,505,047
Weighted average number of dilutive common shares equivalents from stock options		422,571		355,608
Common shares and common share equivalents		17,125,940		16,860,655
Diluted net income per share	$	0.61	$	0.50